Obesity biotech Kailera Therapeutics files for a $100 million IPO
IPO Overview
Kailera Therapeutics, a Phase 3 biotech developing injectable and oral GLP-1s for obesity, filed on Friday with the SEC to raise up to $100 million in an initial public offering.
Kailera is progressing four clinical-stage candidates targeting obesity, leveraging multiple glucagon-like peptide-1 （GLP-1） based mechanisms of action and routes of administration. Its lead candidate, ribupatide （also known as KAI-9531）， is currently being evaluated in global Phase 3 trials as a once-weekly injectable GLP-1/glucose-dependent insulinotropic polypeptide receptor dual agonist peptide. The company is expanding its ribupatide franchise by developing a once-daily oral tablet formulation, oral ribupatide, based on the same peptide as injectable ribupatide.
The Waltham, MA-based company was founded in 2024 and plans to list on the Nasdaq under the symbol KLRA. Kailera Therapeutics filed confidentially on December 19, 2025. J.P. Morgan, Jefferies, Leerink Partners, TD Securities, and Evercore ISI are the joint bookrunners on the deal. No pricing terms were disclosed.
About the Company
We are an advanced clinical-stage biotechnology company focused on elevating the next era of obesity care by advancing a diversified pipeline to provide options for people living with obesity no matter where they are in their treatment journey. We are rapidly progressing four clinical-stage product candidates, leveraging multiple glucagon-like peptide-1, or GLP-1, based mechanisms of action and routes of administration. Our lead product candidate, ribupatide （also known as KAI-9531）， is currently being evaluated in global Phase 3 trials as a once-weekly injectable GLP-1/glucose-dependent insulinotropic polypeptide, or GIP, receptor dual agonist peptide that we believe offers the potential for the greatest weight loss compared to all obesity management medications currently marketed or in development with a tolerability profile that is class-like or better. We are expanding our ribupatide franchise by developing a once-daily oral tablet formulation, oral ribupatide, based on the same peptide as injectable ribupatide, to provide a convenient oral option with the potential for highly differentiated tolerability with compelling weight loss among oral treatments. Additionally, we are advancing a second oral product candidate, KAI-7535, a once-daily small molecule GLP-1 receptor agonist with the potential to improve on the clinical profile of existing oral treatments.
